Evidence of Trospium’s Ability to Mitigate Cholinergic Adverse Events Related to Xanomeline: Phase 1 Study Results 

Breier A, et al. Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results. Psychopharmacology. 2023;240:1191-1198.